Human papillomavirus vaccine may reduce the rate of oral HPV infections in young adults by as much as 88 percent, studies suggest. However, given the vaccine's low rate of uptake in the U.S.—especially in males—the impact of the vaccine on oral HPV infections remains low.
Genentech, a member of the Roche Group, announced that the phase III IMvigor211 study that evaluated Tecentriq (atezolizumab) in people with locally advanced or metastatic urothelial cancer whose disease progressed during or after treatment with a platinum-based chemotherapy did not meet its primary endpoint of overall survival compared to chemotherapy.
The more that is known about defects in specific pathways in pancreatic cancer, the more options researchers will have for developing new treatment options.
AUA released a list of recommendations regarding tests and treatments that are commonly ordered but not always necessary in urology, or urologic management that could be improved, as part of the Choosing Wisely campaign, an initiative of the ABIM Foundation.
AstraZeneca and MedImmune, its global biologics research and development arm, announced positive results for the phase III PACIFIC trial, a randomized, double-blinded, placebo-controlled multi-center trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable non-small cell lung cancer who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy.
A shorter course of radiation therapy given to breast cancer patients following mastectomy is safe and effective and cuts treatment time in half. That is according to data from a phase II clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and other colleagues who examined a hypofractionated regimen given over three weeks versus the traditional six week course of treatment.
FDA granted accelerated approval to Genentech's Tecentriq (atezolizumab) for the initial treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
The American Society for Radiation Oncology issued a clinical guideline for the management of oropharyngeal cancer.
Genetic testing of tumor and blood fluid samples from people with and without one of the most aggressive forms of skin cancer has shown that two new blood tests can reliably detect previously unidentifiable forms of the disease.
